Ulrich Wendt joins UK biotech Alchemab Therapeutics as Chief Business Officer to expand biopharma partnerships

Cambridge, UK – Alchemab Therapeutics has appointed Ulrich Wendt, PhD MBA, as Chief Business Officer (CBO) to expand partnerships with biopharma for the development of novel antibody therapeutics. As a proven dealmaker and strategist, Dr Wendt brings more than a decade of experience in delivering high-value partnerships across all pipeline stages. Before joining Alchemab, he […]